Esperion Therapeutics Stock Buy Hold or Sell Recommendation
ESPR Stock | USD 2.62 0.08 2.96% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Esperion Therapeutics is 'Strong Sell'. Macroaxis provides Esperion Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ESPR positions. The advice algorithm takes into account all of Esperion Therapeutics' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Esperion Therapeutics' buy or sell advice are summarized below:
Real Value 4.63 | Target Price 11.13 | Hype Value 2.61 | Market Value 2.62 | Naive Value 3.3 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Esperion Therapeutics given historical horizon and risk tolerance towards Esperion Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Esperion Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Esperion |
Execute Esperion Therapeutics Buy or Sell Advice
The Esperion recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Esperion Therapeutics. Macroaxis does not own or have any residual interests in Esperion Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Esperion Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Esperion Therapeutics Trading Alerts and Improvement Suggestions
Esperion Therapeutics generated a negative expected return over the last 90 days | |
Esperion Therapeutics has high historical volatility and very poor performance | |
Esperion Therapeutics has a very high chance of going through financial distress in the upcoming years | |
The company reported the previous year's revenue of 116.33 M. Net Loss for the year was (209.25 M) with loss before overhead, payroll, taxes, and interest of (70.42 M). | |
Esperion Therapeutics currently holds about 185.84 M in cash with (135.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.79, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Esperion Therapeutics has a very weak financial position based on the latest SEC disclosures | |
Latest headline from finance.yahoo.com: One Biosciences WelcomesDr. Scott Braunstein and Dr. Vincent Millerto its Board of Directors |
Esperion Therapeutics Returns Distribution Density
The distribution of Esperion Therapeutics' historical returns is an attempt to chart the uncertainty of Esperion Therapeutics' future price movements. The chart of the probability distribution of Esperion Therapeutics daily returns describes the distribution of returns around its average expected value. We use Esperion Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Esperion Therapeutics returns is essential to provide solid investment advice for Esperion Therapeutics.
Mean Return | 0.38 | Value At Risk | -8.54 | Potential Upside | 9.80 | Standard Deviation | 6.34 |
Return Density |
Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Esperion Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Esperion Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Esperion Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Esperion Therapeutics backward and forwards among themselves. Esperion Therapeutics' institutional investor refers to the entity that pools money to purchase Esperion Therapeutics' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Two Sigma Advisers, Llc | 2023-12-31 | 2.1 M | Goldman Sachs Group Inc | 2023-12-31 | 2.1 M | Blackrock Inc | 2023-12-31 | 2.1 M | Jpmorgan Chase & Co | 2023-12-31 | 1.9 M | Tang Capital Management Llc | 2023-09-30 | 1.9 M | Parkman Healthcare Partners Llc | 2023-12-31 | 1.4 M | Renaissance Technologies Corp | 2023-12-31 | 1.4 M | Susquehanna International Group, Llp | 2023-12-31 | 1.4 M | Schonfeld Strategic Advisors Llc | 2023-09-30 | 1.2 M | Wasatch Advisors Inc. | 2023-12-31 | 8.9 M | Two Seas Capital Lp | 2023-12-31 | 7.7 M |
Esperion Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Esperion Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Esperion Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Esperion stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.18 | |
β | Beta against NYSE Composite | 1.50 | |
σ | Overall volatility | 6.26 | |
Ir | Information ratio | 0.04 |
Esperion Therapeutics Volatility Alert
Esperion Therapeutics is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Esperion Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Esperion Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Esperion Therapeutics Fundamentals Vs Peers
Comparing Esperion Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Esperion Therapeutics' direct or indirect competition across all of the common fundamentals between Esperion Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Esperion Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Esperion Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Esperion Therapeutics by comparing valuation metrics with those of similar companies.
Better Than Average | Worse Than Average | Compare Esperion Therapeutics to competition |
Note: Acquisition by Sheldon Koenig of 642000 shares of Esperion Therapeutics at 2.05 subject to Rule 16b-3 [view details]
Esperion Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Esperion . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Esperion Therapeutics Buy or Sell Advice
When is the right time to buy or sell Esperion Therapeutics? Buying financial instruments such as Esperion Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 260.2M | 260.9M | 540.9M | 568.0M | Total Assets | 381.6M | 247.9M | 205.8M | 181.9M |
Use Investing Ideas to Build Portfolios
In addition to having Esperion Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Toys Thematic Idea Now
Toys
Companies producing and distributing toys and different gaming products for kids. The Toys theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Toys Theme or any other thematic opportunities.
View All Next | Launch |
Check out Esperion Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Esperion Stock, please use our How to Invest in Esperion Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Complementary Tools for Esperion Stock analysis
When running Esperion Therapeutics' price analysis, check to measure Esperion Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Esperion Therapeutics is operating at the current time. Most of Esperion Therapeutics' value examination focuses on studying past and present price action to predict the probability of Esperion Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Esperion Therapeutics' price. Additionally, you may evaluate how the addition of Esperion Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Esperion Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Esperion Therapeutics. If investors know Esperion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Esperion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.03) | Revenue Per Share 1.128 | Quarterly Revenue Growth 0.714 | Return On Assets (0.43) | Return On Equity (2.61) |
The market value of Esperion Therapeutics is measured differently than its book value, which is the value of Esperion that is recorded on the company's balance sheet. Investors also form their own opinion of Esperion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Esperion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Esperion Therapeutics' market value can be influenced by many factors that don't directly affect Esperion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Esperion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Esperion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Esperion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.